AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00814346
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 tablet BID
Trial: NCT04228445
Drug: Saline spray
RxNorm normalized name: Saline Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01061645
Drug: MOC31-PE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotoxines
Trial: NCT01740063
Drug: DAS181-F02 formulation
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01740063
Drug: DAS181-F04 formulation
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01740063
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02513238
Drug: Isotonic NaCl
RxNorm normalized name: ISOTON
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04608955
Drug: WX-081
RxNorm normalized name: WX-554
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WX-081 is not licensed yet. WX-081 will be used in arms A, B, C, WX-081+MBT.
Trial: NCT04608955
Drug: Multi-drug background treatment (MBT)
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBT will be used in arm E, F as background treatment. The drugs used in MBT are all licensed drugs, and the treatment complies with the recommendations of WHO guidelines for diagnosis and treatment of tuberculosis.
Trial: NCT02296294
Drug: Elo-mel® (Fresenius Kabi Austria)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an iv isotonic crystalloid fluid therapy at a rate of 0,50ml/kg/min for one hour.
Trial: NCT01806454
Drug: calcium
RxNorm normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00354640
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 milligram tablet PO QD for 14 days
Trial: NCT00876616
Drug: Tacrolimus+Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: FK506 4mg/d,MMF 1.0g/d
Trial: NCT00876616
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CTX 0.75g/m2 BSA
Trial: NCT01041313
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days prior to surgery, start taking one placebo tablet daily; 4 days prior to surgery, increase dose to one placebo tablet twice daily; 2 days prior to surgery, increase dose to 2 placebo tablets in the morning, and one placebo tablet in the evening; on the day of surgery, increase dose to 2 placebo tablets in the morning and 1 placebo tablet in the evening. On the first day after surgery through 14 days after surgery, take 1 placebo tablet twice daily.
Trial: NCT01827150
Drug: Redbull, energy drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A can of 250 mL of the energy drink Redbull will be administered randomly to the subjects
Trial: NCT03625960
Drug: Trichloroacetic Acid
RxNorm normalized name: Trichloroacetic Acid
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trichloroacetic acid is applied to the surface of the wart with a wooden applicator and after drying the area is washed with soap and water in an hour.
Trial: NCT02289495
Drug: GSK2838232
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2838232 will be available as oral suspension dispersion in hydromellulose acetate succinate bulk powder/10, 20 and 50 mg which is to be administered orally QD for 8 days (Part A) or 11 days (Part B), morning dose, following an overnight fast of at least 10 hours
Trial: NCT02289495
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo of Suspension to active dose, administered orally QD for 8 days (Part A) or 11 days (Part B), morning dose, following an overnight fast of at least 10 hours
Trial: NCT00835276
Drug: ALLEGRA® 180 mg tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 180 mg
Trial: NCT01467505
Drug: Immunosuppressant Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (CsA) based immunosuppressant regimen or Tacrolimus (TAC) based immunosuppressant regimen, as per standard practice. Immunosuppressant regimen were not considered study drugs.
Trial: NCT02807623
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The participants will take their first dose of the study drug immediately after influenza vaccine receipt. The medication will be blinded and dispensed by a research pharmacist. The participants will receive instructions on the dosing, frequency and a recommendation to take with food or milk and will be provided a snack with their first dose.
Trial: NCT02807623
Drug: oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will take their first dose of the study drug immediately after influenza vaccine receipt. The medication will be blinded and dispensed by a research pharmacist. The participants will receive instructions on the dosing, frequency and a recommendation to take with food or milk and will be provided a snack with their first dose.
Trial: NCT02221219
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: indomethacin at standard dose for prevention of intraventricular hemorrhage in preterm infants
Trial: NCT02221219
Drug: placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline infusion to match input of indomethacin treatment group (and serve as drug-dosing 'blinding' for bedside staff)
Trial: NCT02613871
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90/400 mg FDC tablet administered orally once daily
Trial: NCT01483248
Drug: Conventional therapy plus placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 of the enrolled patients were assigned to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
Trial: NCT00437346
Drug: Lanzo Melt
RxNorm normalized name: Feldene Melt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg, od, 1/2 h before meal
Trial: NCT02116543
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00507689
Drug: FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg was administered as a fixed-dose combination tablet orally once daily.
Trial: NCT02749578
Drug: MGL-3196
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00031135
Drug: Choline Chloride
RxNorm normalized name: Choline Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01518634
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-week of wash-out, one week of 10 mg study drug, 10 weeks of 25-75 mg study drug, four weeks of phasing-out and finaly two weeks after ther last dose of study drug to monito adverse events.
Trial: NCT01057758
Drug: SIMVASTATIN
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 60 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study ICU.
Trial: NCT01057758
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive one placebo by mouth or feeding tube daily for 28 days or until discharged form study ICU
Trial: NCT05242926
Drug: ModraDoc006/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One time bi-daily dosing (30/20 mg) of ModraDoc006 in combination with ritonavir 100 mg tablets
Trial: NCT00779545
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One, two, or four sprays of placebo are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks.
Trial: NCT00170872
Drug: Lumiracoxib
RxNorm normalized name: Lumiracoxib
DrugBank: Lumiracoxib (DB01283)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03861767
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo in doses of 1, 2 and 3 tablets to coincide with the 500, 1000, and 1500 mg arms.
Trial: NCT00366938
Drug: Lumiracoxib
RxNorm normalized name: Lumiracoxib
DrugBank: Lumiracoxib (DB01283)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01156480
Drug: hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects in hydrocortisone group will receive 3mg/kg/day divided every 8 hours via IV route for 3 days, followed by 2mg/kg/day divided every 8 hours IV for 1 day, followed by 1.5mg/kg/day divided every 8 hours IV for 1 day, followed by 1mg/kg/day divided every 12 hours for 1 day, followed by 0.5mg/kg/day in single dose for one day. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
Trial: NCT01156480
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in placebo group will receive a volume of placebo equal to the hydrocortisone group, on the same dosing schedule, with doses given every 8 hours via IV route for 3 days, followed by placebo every 8 hours IV for 1 day, followed by placebo every 8 hours IV for 1 day, followed by placebo every 12 hours for 1 day, followed by placebo in single dose for one day. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
Trial: NCT00702468
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contains no active drug and is delivered in 100 microlitre actuations by a pump action oromucosal spray
Trial: NCT03400488
Drug: AZD5718 oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In all cohorts, randomized subjects will receive orally AZD5718 oral suspension SAD (60 mg) on Day 1 and MAD (180 mg, 360 mg and 600 mg) from Days 3 to 10. On Day 2, no dose will be given. In total each subject will receive 9 doses of AZD5718.
Trial: NCT00000376
Drug: Desipramine
RxNorm normalized name: Desipramine
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00845832
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv on days 1 and 15 (Parts 1 and 2)
Trial: NCT00888979
Drug: Nicotrol Inhaler
RxNorm normalized name: Nicotrol Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of nicotine per one inhaler cartridge. Inhaler use will substitute the usual smoking pattern
Trial: NCT00309088
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02129582
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00429559
Drug: Hycamptin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.75mg/m2 IV on day 1 every week for 3 weeks in cycles of 4 weeks Number of cycles: until progression
Trial: NCT04408937
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules for oral administration
Trial: NCT03226899
Drug: XOI
RxNorm normalized name: TOXOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants must be on a stable, medically appropriate dose of XOI as their sole urate-lowering therapy (ULT) indicated for the treatment of gout for at least 4 weeks prior to Screening and throughout the Screening Period. This stable dose of XOI will be maintained throughout the study period.
Trial: NCT03226899
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo oral tablet
Trial: NCT03226899
Drug: corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gout flare prophylaxis: Participants unable to take colchicine are permitted to take a short course of low-dose oral corticosteroids up to the Month 3 study visit
Trial: NCT01291381
Drug: Pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For patients randomized to non-SIT group, persistent rhinitis was managed with pharmacotherapy including intranasal steroids and oral antihistamines. Intranasal steroids were kept at the same dose during the study and antihistamines were used as required.
Trial: NCT00640484
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo once a day, in the morning~(1 puff of placebo pMDI + 1 puff of placebo pMDI)
Trial: NCT02052219
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered subcutaneously
Trial: NCT01351272
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00984984
Drug: methylprednisolone PO
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 capsules Methylprednisolone 100 mg and 50 ml IV NaCl 0,9% (syringe pump 30 mn to 2 h, every day during 3 days
Trial: NCT00984984
Drug: methylprednisolone IV
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Methylprednisolone 1 g in 50 ml NaCl 0,9% (syringe pump 30 mn to 2 h) and 10 capsules of placebo, every day during 3 days
Trial: NCT02210806
Drug: Proventil® MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose 90 mcg, 1 inhalation
Trial: NCT02210806
Drug: Proventil® MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose 90 mcg, 2 inhalations
Trial: NCT02084485
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT00657046
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules with mannitol substituted for droxidopa
Trial: NCT00546624
Drug: MK0777
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01359592
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01359592
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00020449
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03881111
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to pembrolizumab (saline) administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
Trial: NCT00623324
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets to match the number of active tablets
Trial: NCT03591718
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for injection
Trial: NCT01337336
Drug: Anticholinergics
RxNorm normalized name: Anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiotropium; ipratropium alone; or ipratropium + albuterol
Trial: NCT02241564
Drug: Switch from calcineurin inhibitor to an mTOR inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01285817
Drug: celecoxib, Vinblastine, Cyclophosphamide , methotrexate ,
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03393494
Drug: Epiduo Topical Product
RxNorm normalized name: Epiduo Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RLD product
Trial: NCT03393494
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel
Trial: NCT02528825
Drug: Remifentanil titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial concentration being 1.5ng/ml for the first patient The smooth emergence was defined as extubation without cough-a strong and sudden contraction of the abdomen. The predetermined concentration was decreased by 0.5 ng/ml for the next patient if the patient did not cough during emergence and similarly, if the patient coughed anytime during emergence, it was considered failed smooth emergence and predetermined concentration was increased by 0.5 ng/ml.
Trial: NCT03004365
Drug: C16G2 Varnish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial Peptide
Trial: NCT03004365
Drug: Placebo Varnish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01305733
Drug: The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline
Trial: NCT00373464
Drug: etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01316380
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
Trial: NCT00044694
Drug: Placebo 0.01 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.01 mL subcutaneously injected twice daily
Trial: NCT00044694
Drug: Placebo 0.03 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.03 mL subcutaneously injected twice daily
Trial: NCT00044694
Drug: Placebo 0.04 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.04 mL subcutaneously injected twice daily
Trial: NCT00044694
Drug: AC2993 2.5 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 2.5 mcg (0.01 mL) subcutaneously injected twice daily
Trial: NCT00044694
Drug: AC2993 5.0 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 5.0 mcg (0.02 mL) subcutaneously injected twice daily
Trial: NCT00044694
Drug: AC2993 7.5 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 7.5 mcg (0.03 mL) subcutaneously injected twice daily
Trial: NCT00044694
Drug: AC2993 10.0 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 10.0 mcg (0.04 mL) subcutaneously injected twice daily
Trial: NCT02174393
Drug: Post-Universal Peel Skin Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Gentle Antioxidant Soothing Cleanser daily~* Physical Sunscreen daily~* Soothing recovery ointment fortified with silver only when peeling occurs~* After completely peeling, vitamin c product in the morning and the retinol in the evening
Trial: NCT04091425
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-925 placebo-matching IV infusion
Trial: NCT02468297
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Experiment group took placebo only in the first week. Control group took ibuprofen(400mg, TID) only in the first week. No more placebo or medicine was prescribed to either two groups since the second week.
Trial: NCT03915340
Drug: Rytmonorm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rytmonorm is manufactured by Famar Lyon, France (MAH: Mylan Healthcare GmbH, Germany). Each tablet contains 300 mg of propafenone hydrochloride.
Trial: NCT01503008
Drug: Regularly prescribed diabetes medicines (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors)
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hypoglycemics (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors) at subjects' regularly prescribed doses; glucometer
Trial: NCT01380223
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.V. infusion of placebo for 8 hr
Trial: NCT01859923
Drug: Optimized Background Regimen (OBR)
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selection and administration of the treatment medications (i.e. OBRs) was based on Search Results Web result with site links~World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines. Study Investigator could change OBR for a participant based on his/her tolerability and drug susceptibility testing (DST) results.
Trial: NCT03787186
Drug: GLPG1690 film-coated tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single oral dose of GLPG1690
Trial: NCT03787186
Drug: [14C]-GLPG1690 solution for infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a 15-minute IV infusion \[14C\]-GLPG1690
Trial: NCT03787186
Drug: [14C]-GLPG1690 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose of \[14C\]-GLPG1690
Trial: NCT00325455
Drug: MK0859
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00764361
Drug: doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.0% doxycycline gel applied topically to the wound once daily for 20 weeks
Trial: NCT00764361
Drug: placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo gel applied topically to the wound once daily for 20 weeks
Trial: NCT04306354
Drug: placebo nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray with placebo solution (2% odor-generating propolis essence + the same vehicle as intra-nasal oxytocin: 0.05% citric acid, 0.9% sodium chloride, 1% glycerol, 0.54% disodium phosphate, 0.2% methylparaben + propylparaben, 1% sorbitol, 80% water) twice daily as adjunctive treatment to conventional treatment.